A compound represented by Formula (1) given below. (In the formula, R.sup.1 represents a hydrogen atom or a methyl group, X.sup.1 represents a C.sub.1 to 9 alkylene group, or a C.sub.3 to 6 alkylene group in which at least one hydrogen is replaced with an acryloxy group or a methacryloxy group, l.sup.1 represents an integer from 0 to 3, Q.sup.1 represents a hydrogen atom or Formula (2) given below (In the formula, R.sup.2 represents a hydrogen atom or a methyl group, X.sup.2 represents a C.sub.1 to 9 alkylene group, or a C.sub.3 to 6 alkylene group in which at least one hydrogen is replaced with an acryloxy group or a methacryloxy group, l.sup.2 represents an integer from 0 to 3, and * represents a bonding site), and Q.sup.2 represents a hydrogen atom or Formula (3) given below (In the formula, R.sup.3 represents a hydrogen atom or a methyl group, X.sup.3 represents a C.sub.1 to 9 alkylene group, or a C.sub.3 to 6 alkylene group in which at least one hydrogen is replaced with an acryloxy group or a methacryloxy group, l.sup.3 represents an integer from 0 to 3, and * represents a bonding site).)

A light-absorbing material includes a compound represented by the formula (1) below. In the formula (1), L.sup.1 to L.sup.3 are each independently represented by the formula (2) or (3) below:

##STR00001##

A light-absorbing material includes a compound represented by the formula (1) below. In the formula (1), L.sup.1 to L.sup.3 are each independently represented by the formula (2) or (3) below:

##STR00001##

Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.

Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

The present invention relates to compounds capable of forming metal-organic frameworks (MOFs), particularly f-block metal MOFs which selectively sorb one component (e.g. para-xylene) from a mixture of components (e.g. m-/p-xylene mixture). The invention also relates to methods of producing and using said compounds.

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).